Insurance covers stem cell treatments only for a narrow set of conditions, mainly blood cancers and bone marrow disorders. If you’re looking into stem cell injections for joint pain, arthritis, or sports injuries, your insurance will almost certainly deny the claim. The distinction comes down to what type of stem cell therapy you’re asking about and what condition it’s treating.
What Insurance Actually Covers
The stem cell procedures that insurance reliably pays for are hematopoietic stem cell transplants, commonly known as bone marrow transplants. These involve replacing damaged blood-forming cells in patients with leukemia, lymphoma, aplastic anemia, and certain other blood disorders. Medicare has covered allogeneic stem cell transplants (using a donor’s cells) for leukemia and aplastic anemia since 1978. As of March 2024, Medicare expanded coverage to include patients with myelodysplastic syndromes who meet specific risk thresholds.
Private insurers like Aetna, Anthem, Cigna, and others follow similar patterns. They cover stem cell transplants when the procedure is an established part of cancer treatment. A 2013 analysis by the National Marrow Donor Program found that 28 states specifically mentioned stem cell transplant benefits in their essential health benefit benchmark plans, giving patients in those states additional coverage assurance through marketplace insurance.
Autologous transplants, where your own stem cells are harvested and returned to you after intensive chemotherapy, are also covered for conditions like acute leukemia in remission when relapse risk is high and no matched donor is available.
Why Orthopedic Stem Cell Injections Are Different
The stem cell injections marketed for knee osteoarthritis, rotator cuff tears, back pain, and other musculoskeletal conditions occupy an entirely different category. These typically involve extracting cells from your own bone marrow or fat tissue, processing them, and injecting them into a damaged joint or tendon. Major insurers classify these procedures as experimental.
Aetna’s coverage policy for knee osteoarthritis, for example, labels stem cell therapy “experimental and investigational because the effectiveness of the approach has not been established.” A 2025 study published in HSS Journal examined the references Aetna cited to justify that denial and found something striking: 70% of the sources Aetna itself referenced actually demonstrated that mesenchymal stem cell therapy was effective for orthopedic applications. The researchers examined five major insurers with publicly accessible policies (Aetna, Anthem, Cigna, HCSC, and Highmark) and found a similar pattern across the board. The evidence cited in the denial policies often didn’t support the denials themselves.
Despite this disconnect, the practical reality hasn’t changed. None of these major insurers cover stem cell injections for joint or orthopedic conditions as of 2025. The FDA has not approved stem cell injection products for osteoarthritis or musculoskeletal repair, and insurers use that regulatory gap as their primary justification.
What FDA Approval Looks Like
The FDA has approved a limited number of cellular therapy products. Most are cord blood products used in bone marrow transplants for blood disorders. One approved product, remestemcel-L, treats a specific complication of bone marrow transplants in children. Another, sipuleucel-T, is a cellular immunotherapy for prostate cancer. None of these are the type of stem cell injection you’d receive at an orthopedic or regenerative medicine clinic.
Many clinics offering stem cell injections for joints operate in a regulatory gray area. They argue that because they’re using your own cells and processing them minimally, the procedure doesn’t require FDA approval. The FDA has pushed back on this interpretation, but enforcement has been inconsistent. For insurance purposes, the lack of formal approval is the key barrier.
Out-of-Pocket Costs for Joint Injections
Because insurance doesn’t cover orthopedic stem cell injections, you’ll pay the full cost yourself. Prices at U.S. clinics typically range from $3,000 to $10,000 per injection, depending on the source of cells, the joint being treated, and the clinic’s pricing structure. Some clinics charge $5,000 to $8,000 for a single knee injection. Multiple joints or repeat treatments push costs higher. These prices are not standardized, and there’s significant variation from one provider to the next.
Some clinics offer financing plans or package pricing, but the total remains a significant expense with no guarantee of results. The lack of large, definitive clinical trials means you’re paying for a treatment whose effectiveness hasn’t been proven to the standard that regulators or insurers require.
Clinical Trials as an Alternative
Enrolling in a clinical trial can reduce or eliminate the cost of stem cell treatment. According to the National Cancer Institute, the sponsor of a clinical trial typically covers research-related costs, including the study treatment itself, lab tests done purely for the trial, and imaging or doctor visits required by the study protocol. Your insurance often covers the routine patient care costs you’d have regardless of trial participation, like standard office visits and diagnostic tests.
For orthopedic stem cell therapies specifically, clinical trials are ongoing at academic medical centers across the country. Participating gives you access to the treatment under medical oversight, with the added benefit of contributing to the evidence base that could eventually change coverage decisions. ClinicalTrials.gov lists active studies you can search by condition and location.
Appealing a Coverage Denial
If your situation involves a stem cell transplant for cancer or a blood disorder and your insurer denies coverage, you have a legitimate basis for appeal. The process typically involves submitting a letter of medical necessity from your treating physician that documents your diagnosis, explains why the transplant is the appropriate treatment, and cites clinical evidence supporting the procedure for your specific condition.
For orthopedic stem cell injections, appeals are far less likely to succeed. Without FDA approval or inclusion in national coverage determinations, the insurer’s “experimental” classification is difficult to overturn. Some patients have tried coding the procedure under related treatments like platelet-rich plasma injections, but this creates billing complications and rarely results in coverage.
The gap between the growing clinical evidence for orthopedic stem cell therapy and the insurance industry’s willingness to cover it remains wide. Until large randomized trials produce results strong enough to shift FDA and insurer positions, patients seeking these injections for joint pain will continue paying out of pocket.